An innovative phase II trial to establish proof of efficacy and optimal dose of a new inhaled epithelial sodium channel inhibitor BI 1265162 in adults and adolescents with cystic fibrosis: BALANCE-CF<sup>TM</sup> 1.

Goss, Christopher H; Jain, Raksha; Seibold, Wolfgang; Picard, Anne-Caroline; Hsu, Ming-Chi; Gupta, Abhya; Fajac, Isabelle

An innovative phase II trial to establish proof of efficacy and optimal dose of a new inhaled epithelial sodium channel inhibitor BI 1265162 in adults and adolescents with cystic fibrosis: BALANCE-CF^TM 1.

Goss, Christopher H; Jain, Raksha; Seibold, Wolfgang; Picard, Anne-Caroline; Hsu, Ming-Chi; Gupta, Abhya; Fajac, Isabelle.

Afiliación

Goss CH; Dept of Medicine, Dept of Pediatrics, University of Washington, Seattle Children's Hospital & Research Institute, Seattle, WA, USA.
Jain R; Dept of Internal Medicine, University of Texas Southwestern Med Center, Dallas, TX, USA.
Seibold W; Boehringer Ingelheim, Biberach an der Riss, Germany.
Picard AC; Boehringer Ingelheim, Reims, France.
Hsu MC; Boehringer Ingelheim (China) Investment Co. Ltd, Shanghai, China.
Gupta A; Boehringer Ingelheim, Biberach an der Riss, Germany.
Fajac I; AP-HP, Centre Université de Paris, Paris, France.

ERJ Open Res ; 6(4)2020 Oct.

Article en En | MEDLINE | ID: mdl-33313307

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Banco de datos: MEDLINE Tipo de estudio: Clinical_trials Idioma: En Año: 2020 Tipo del documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Banco de datos: MEDLINE Tipo de estudio: Clinical_trials Idioma: En Año: 2020 Tipo del documento: Article